A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 16 Sep 2020 to 5 Oct 2019.
    • 07 Aug 2017 Planned primary completion date changed from 23 Jan 2019 to 16 Jan 2019.
    • 20 Jun 2017 Planned number of patients changed from 50 to 38.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top